Allianz Asset Management
CRVS icon

Allianz Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Allianz Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-134,400
Closed -$2.79M – 2622
2017
Q1 		$2.79M Buy
134,400
+18,995
+16% +$298K ﹤0.01% 1867
2016
Q4 		$1.65M Hold
115,405
– – ﹤0.01% 2044
2016
Q3 		$1.87M Sell
115,405
-9,595
-8% -$138K ﹤0.01% 2007
2016
Q2 		$1.78M Hold
125,000
– – ﹤0.01% 1977
2016
Q1 		$1.81M Buy
+125,000
New +$1.79M ﹤0.01% 1859

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allianz Asset Management's CRVS Position: Q2 2017 in Review

Allianz Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2017, closing a stake of 134,400 shares — an estimated $2.79M sold.

Allianz Asset Management first reported a position in CRVS in Q1 2016 and held it in 5 quarters. The position peaked at $2.79M in Q1 2017. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

  • Allianz Asset Management reported no remaining Corvus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Allianz Asset Management sold 134,400 Corvus Pharmaceuticals shares in Q2 2017, an estimated $2.79M.
  • Allianz Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Allianz Asset Management's Corvus Pharmaceuticals position peaked at $2.79M in Q1 2017.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on Allianz Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.